{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:02:10Z","timestamp":1790827330462,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cyto.2023.156271","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T06:45:27Z","timestamp":1686897927000},"page":"156271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The present roles and future perspectives of Interleukin-6 in biliary tract cancer"],"prefix":"10.1016","volume":"169","author":[{"given":"Meng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruisi","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihui","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-3924","authenticated-orcid":false,"given":"Tongsen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0005","first-page":"225","article-title":"Cancer statistics 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA: Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199610000-00005","article-title":"Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors","volume":"224","author":"Nakeeb","year":"1996","journal-title":"Ann. Surg."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ags3.12334","article-title":"Genetic analysis in the clinical management of biliary tract cancer","volume":"4","author":"Wakai","year":"2020","journal-title":"Ann. Gastroenterol. Surg."},{"issue":"Suppl. 1","key":"10.1016\/j.cyto.2023.156271_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000167859","article-title":"Epigenetic alterations in cholangiocarcinoma-sustained IL-6\/STAT3 signaling in cholangio- carcinoma due to SOCS3 epigenetic silencing","volume":"79","author":"Isomoto","year":"2009","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13046-022-02386-2","article-title":"New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming","volume":"41","author":"Colyn","year":"2022","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0030","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Rizvi","year":"2013","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0035","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-022-02394-2","article-title":"The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease","volume":"41","author":"Cigliano","year":"2022","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0040","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/hep.27687","article-title":"IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism","volume":"61","author":"Yamada","year":"2015","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0045","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3892\/mmr.2015.4706","article-title":"Interleukin-6 induces epithelial-mesenchymal transition in human intrahepatic biliary epithelial cells","volume":"13","author":"Jiang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0050","first-page":"343","article-title":"The m6A writers regulated by the IL-6\/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma","volume":"19","author":"Ye","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20966","article-title":"Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells","volume":"42","author":"Isomoto","year":"2005","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"7","key":"10.1016\/j.cyto.2023.156271_b0060","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1053\/j.gastro.2005.03.010","article-title":"Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells","volume":"128","author":"Kobayashi","year":"2005","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0065","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jhep.2005.10.030","article-title":"Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes","volume":"44","author":"Meng","year":"2006","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0070","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/hep.510300522","article-title":"Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line","volume":"30","author":"Park","year":"1999","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/hep.23381","article-title":"MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes","volume":"51","author":"Braconi","year":"2010","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0080","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.onc.1210648","article-title":"Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes","volume":"27","author":"Meng","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0085","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.32232","article-title":"IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma","volume":"75","author":"Li","year":"2022","journal-title":"Hepatology (Baltimore, Md.)."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/cas.13433","article-title":"Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity","volume":"109","author":"Tsukamoto","year":"2018","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/82763","article-title":"IL-6 switches the differentiation of monocytes from dendritic cells to macrophages","volume":"1","author":"Chomarat","year":"2000","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0105","first-page":"3844","article-title":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation","volume":"173","author":"Park","year":"2004","journal-title":"J. Immun. (Baltimore, Md. : 1950)"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0110","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2014.11.009","article-title":"Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis","volume":"41","author":"Wang","year":"2014","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","article-title":"The two faces of IL-6 in the tumor microenvironment","volume":"26","author":"Fisher","year":"2014","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.cyto.2023.156271_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155654","article-title":"Role of IL-6 in the commitment of T cell subsets","volume":"146","author":"Korn","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2023.156271_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0130","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.cyto.2023.156271_b0135","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) Immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","article-title":"Targeting interleukin-6 in inflammatory autoimmune diseases and cancers","volume":"141","author":"Yao","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2023.156271_b0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s11658-018-0122-0","article-title":"The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice","volume":"23","author":"Liang","year":"2018","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.cyto.2023.156271_b0155","first-page":"561","article-title":"PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism","volume":"8","author":"Alsaab","year":"2017","journal-title":"Combinations, Clin. Outcome, Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.cyto.2023.156271_b0160","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Piha-Paul","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.cyto.2023.156271_b0165","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/2159-8290.CD-21-1640","article-title":"Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0170","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s10620-019-05787-0","article-title":"Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma","volume":"65","author":"Dong","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.cyto.2023.156271_b0175","doi-asserted-by":"crossref","unstructured":"G. Schett, Physiological effects of modulating the interleukin-6 axis, Rheumatology (Oxford, England). 57(suppl_2) (2018) ii43-ii50, https:\/\/doi.org\/10.1093\/rheumatology\/kex513.","DOI":"10.1093\/rheumatology\/kex513"},{"issue":"9","key":"10.1016\/j.cyto.2023.156271_b0180","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0190","first-page":"1248","article-title":"Interleukin-6 as a therapeutic target, Clinical Cancer Research : an Official Journal of the American Association For","volume":"21","author":"Rossi","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0195","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S2213-2600(21)00103-X","article-title":"Interleukin-6: obstacles to targeting a complex cytokine in critical illness","volume":"9","author":"McElvaney","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"24","key":"10.1016\/j.cyto.2023.156271_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413496","article-title":"Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-\u03baB-Dependent Pathway","volume":"22","author":"Dana","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0205","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/hep.26705","article-title":"Gankyrin promotes tumor growth and metastasis through activation of IL-6\/STAT3 signaling in human cholangiocarcinoma","volume":"59","author":"Zheng","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0210","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41419-019-1506-4","article-title":"Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6\/STAT3\/VEGFA signaling pathway","volume":"10","author":"Leng","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0215","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-2559.1998.00445.x","article-title":"Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma","volume":"33","author":"Sugawara","year":"1998","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0220","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1440-1746.1994.tb01275.x","article-title":"Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line","volume":"9","author":"Okada","year":"1994","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2022.04.028","article-title":"\u03b2-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma","volume":"163","author":"Zhang","year":"2022","journal-title":"Gastroenterology"},{"issue":"21","key":"10.1016\/j.cyto.2023.156271_b0230","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.lfs.2005.10.015","article-title":"Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes","volume":"78","author":"Yamagiwa","year":"2006","journal-title":"Life Sci."},{"issue":"21","key":"10.1016\/j.cyto.2023.156271_b0235","doi-asserted-by":"crossref","first-page":"10517","DOI":"10.1158\/0008-5472.CAN-06-2130","article-title":"Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression","volume":"66","author":"Wehbe","year":"2006","journal-title":"Cancer Res."},{"issue":"Suppl 1","key":"10.1016\/j.cyto.2023.156271_b0240","first-page":"108","article-title":"Diagnostic and prognostic biomarkers in cholangiocarcinoma, Liver International : Official Journal of the International Association For the Study of the","volume":"39","author":"Macias","year":"2019","journal-title":"Liver"},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0245","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000658-199803000-00012","article-title":"Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker","volume":"227","author":"Goydos","year":"1998","journal-title":"Ann. Surg."},{"issue":"10","key":"10.1016\/j.cyto.2023.156271_b0250","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/j.1572-0241.2007.01403.x","article-title":"Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy","volume":"102","author":"Cheon","year":"2007","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.cyto.2023.156271_b0255","doi-asserted-by":"crossref","first-page":"S1524","DOI":"10.1245\/s10434-015-4782-y","article-title":"Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarcinoma","volume":"22","author":"Asukai","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.cyto.2023.156271_b0260","doi-asserted-by":"crossref","unstructured":"K. Utsumi, Y. Takai, T. Tada, et al., Enhanced production of IL-6 in tumor-bearing mice and determination of cells responsible for its augmented production, Journal of Immunology (Baltimore, Md. : 1950). 145(1) (1990) 397-403.","DOI":"10.4049\/jimmunol.145.1.397"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0265","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08941939.2017.1358310","article-title":"Clinical Significance of Soluble Intercellular Adhesion Molecule-1 and Interleukin-6 in Patients with Extrahepatic Cholangiocarcinoma","volume":"31","author":"Shimura","year":"2018","journal-title":"J. Invest. Surg.: Off. J. Acad. Surg. Res."},{"issue":"11","key":"10.1016\/j.cyto.2023.156271_b0270","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.30571","article-title":"A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma","volume":"123","author":"Goyal","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0275","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3892\/etm.2011.424","article-title":"Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis","volume":"3","author":"Yoshitomi","year":"2012","journal-title":"Exp. Ther. Med."},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41416-018-0132-8","article-title":"Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial","volume":"119","author":"Backen","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0285","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","article-title":"Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma","volume":"73","author":"Zhang","year":"2020","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.cyto.2023.156271_b0290","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092134","article-title":"Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse","volume":"13","author":"Thongchot","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0295","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.cyto.2023.156271_b0300","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/1078-0432.CCR-09-3122","article-title":"Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer","volume":"16","author":"Dorff","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.cyto.2023.156271_b0305","first-page":"5759","article-title":"Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer, Clinical Cancer Research : an Official Journal of the American Association For","volume":"16","author":"Guo","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.cyto.2023.156271_b0310","first-page":"974","article-title":"Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer, Journal of Thoracic Oncology : Official Publication of the International Association For the Study of","volume":"9","author":"Song","year":"2014","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0315","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/jgh.15307","article-title":"Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma","volume":"36","author":"Nguyen","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0320","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bbadis.2018.11.006","article-title":"Pharmacologic IL-6R\u03b1 inhibition in cholangiocarcinoma promotes cancer cell growth and survival, Biochimica Et Biophysica Acta","volume":"1865","author":"Kleinegger","year":"2019","journal-title":"Mol. Basis Disease"},{"key":"10.1016\/j.cyto.2023.156271_b0325","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.897368","article-title":"Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma","volume":"13","author":"Kittirat","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051154","article-title":"STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma","volume":"14","author":"Ploeger","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.cyto.2023.156271_b0335","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0340","doi-asserted-by":"crossref","DOI":"10.1111\/cas.14752","article-title":"Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer","volume":"112","author":"Zhang","year":"2021","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0345","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.201040979","article-title":"PD-L1 expression on tolerogenic APCs is controlled by STAT-3","volume":"41","author":"W\u00f6lfle","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0350","article-title":"IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma, Journal For Immunotherapy of","volume":"8","author":"Zhang","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.cyto.2023.156271_b0355","doi-asserted-by":"crossref","first-page":"12632","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.cyto.2023.156271_b0365","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1172\/JCI126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0370","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.cyto.2023.156271_b0375","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.ccell.2021.11.010","article-title":"Toward a better understanding of T cells in cancer","volume":"39","author":"Oh","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2017.02.128","article-title":"IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model","volume":"486","author":"Liu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.cyto.2023.156271_b0385","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1158\/1078-0432.CCR-18-2402","article-title":"Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth","volume":"25","author":"Lamano","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cyto.2023.156271_b0390","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.12659\/MSM.907439","article-title":"Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model","volume":"24","author":"Li","year":"2018","journal-title":"Medical Science Monitor: Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0395","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cyto.2023.156271_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155976","article-title":"Blockade of IL-6 inhibits tumor immune evasion and improves anti-PD-1 immunotherapy","volume":"158","author":"Li","year":"2022","journal-title":"Cytokine"},{"issue":"7930","key":"10.1016\/j.cyto.2023.156271_b0405","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","article-title":"PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program","volume":"610","author":"Hashimoto","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2009.06.018","article-title":"CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages","volume":"16","author":"DeNardo","year":"2009","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.cyto.2023.156271_b0415","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1158\/1078-0432.CCR-14-1015","article-title":"Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma","volume":"20","author":"Zelba","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cyto.2023.156271_b0420","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.1103797","article-title":"The key role of IL-6-arginase cascade for inducing dendritic cell-dependent CD4(+) T cell dysfunction in tumor-bearing mice","volume":"190","author":"Narita","year":"2013","journal-title":"J. Immunol. (Baltimore, Md. : 1950)"},{"key":"10.1016\/j.cyto.2023.156271_b0425","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1038\/ncomms7702","article-title":"IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age","volume":"6","author":"Tsukamoto","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.cyto.2023.156271_b0430","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.174.5.2720","article-title":"IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation","volume":"174","author":"Yang","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2023.156271_b0435","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2023.156271_b0440","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.immunol.18.1.451","article-title":"Signaling and transcription in T helper development","volume":"18","author":"Murphy","year":"2000","journal-title":"Annu. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2023.156271_b0445","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb. perspect. biol."},{"key":"10.1016\/j.cyto.2023.156271_b0450","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy","volume":"9","author":"Mortara","year":"2018","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.cyto.2023.156271_b0455","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined Blockade of IL6 and PD-1\/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cyto.2023.156271_b0460","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","article-title":"Mechanisms of immune activation and regulation: lessons from melanoma","volume":"22","author":"Kalaora","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cyto.2023.156271_b0465","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2019.03.014","article-title":"Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling","volume":"131","author":"Rice","year":"2019","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"23","key":"10.1016\/j.cyto.2023.156271_b0470","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236132","article-title":"Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity","volume":"13","author":"Matsuo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.cyto.2023.156271_b0475","doi-asserted-by":"crossref","first-page":"5535578","DOI":"10.1155\/2021\/5535578","article-title":"IL-6 Promotes the Proliferation and Immunosuppressive Function of Myeloid-Derived Suppressor Cells via the MAPK Signaling Pathway in Bladder Cancer","volume":"2021","author":"Zheng","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"11","key":"10.1016\/j.cyto.2023.156271_b0480","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.cyto.2023.156271_b0485","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","article-title":"A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer","volume":"26","author":"Dijkgraaf","year":"2015","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2023.156271_b0490","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2023.156271_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101697","article-title":"The hormetic and hermetic role of IL-6","volume":"80","author":"Forcina","year":"2022","journal-title":"Ageing Res. Rev."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466623001497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:50:36Z","timestamp":1760910636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466623001497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":99,"alternative-id":["S1043466623001497"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156271","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The present roles and future perspectives of Interleukin-6 in biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2023.156271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156271"}}